Ann: Amplia Provides Updated Investor Presentation, page-5

I was going to add some, but I withdrew after reading this ann.
First, it seems the schedule for phase 2 IPF is stretching, from Q1 22 in the previous announcements to Q3 22 so far. May be due to uncertainties about formulation of the inhaling form of the drug.
Second, The first upcoming milestone which is pancreatic cancer phase 2 interim results, will be in the next 18 months.
As a usual investor with limited money to invest, this is a little bit long term.
I changed my plan from buy, to observe and watch to buy in a dip later.